Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 3
2022 2
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Lrp1 is a host entry factor for Rift Valley fever virus.
Ganaie SS, Schwarz MM, McMillen CM, Price DA, Feng AX, Albe JR, Wang W, Miersch S, Orvedahl A, Cole AR, Sentmanat MF, Mishra N, Boyles DA, Koenig ZT, Kujawa MR, Demers MA, Hoehl RM, Moyle AB, Wagner ND, Stubbs SH, Cardarelli L, Teyra J, McElroy A, Gross ML, Whelan SPJ, Doench J, Cui X, Brett TJ, Sidhu SS, Virgin HW, Egawa T, Leung DW, Amarasinghe GK, Hartman AL. Ganaie SS, et al. Cell. 2021 Sep 30;184(20):5163-5178.e24. doi: 10.1016/j.cell.2021.09.001. Epub 2021 Sep 23. Cell. 2021. PMID: 34559985 Free PMC article.
Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
McMillen CM, Megli C, Radisic R, Skvarca LB, Hoehl RM, Boyles DA, McGaughey JJ, Bird BH, McElroy AK, Hartman AL. McMillen CM, et al. bioRxiv [Preprint]. 2024 Jun 1:2024.05.31.596800. doi: 10.1101/2024.05.31.596800. bioRxiv. 2024. Update in: J Virol. 2024 Aug 20;98(8):e0098324. doi: 10.1128/jvi.00983-24 PMID: 38854055 Free PMC article. Updated. Preprint.
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, Barbeau DJ, Crossland NA, Hoehl RM, Schrauf S, White AG, Borish HJ, Tomko JA, Frye LJ, Scanga CA, Flynn JL, Martin A, Gerke C, Hartman AL, Duprex WP. Nambulli S, et al. J Virol. 2024 May 14;98(5):e0176223. doi: 10.1128/jvi.01762-23. Epub 2024 Apr 2. J Virol. 2024. PMID: 38563762 Free PMC article.
11 results